August 30, 2016

Two recent unanimous approval recommendations from FDA advisory committees regarding biosimilars is a signal of growing scientific acceptance and understanding of the biosimilar regulatory pathway, suggested The National Law Review in a report Tuesday. The National Law Review has created a chart summarizing pending and approved BLAs for biosimilars using publicly available information, the publication noted, but there are still two barriers to entry. As biosimilars gain FDA approval, patent issues remain a barrier and the exorbitant R&D cost prevent significant price disparities. Accordingly, insurers may be slow to add biosimilars to the formulary, The National Law Review suggested. (The National Law Review)

August 22, 2016

The app allows hemophilia patients to record bleeding episodes and treatment while facilitating easy information sharing with their caregivers, physicians, pharmacists and nurses. 

August 22, 2016

Pfizer's proposed acquisition of biopharmaceutical company Medivation is aimed at making them a leader in the oncology space while working to bring two of Medivation's most promising late-stage assets to patients. 

August 18, 2016
 The acquisition raises the number of Genoa pharmacies in Michigan to 24, with more than 325 nationally, most of which are located onsite at community mental health centers.
August 18, 2016
The New Jersey location will consolidate the operations for its specialty brands groups, and the company is continuing its investment in the St. Louis, Mo. area, including construction on its manufacturing facility there. 
August 18, 2016

Among the portfolio’s products are U.S. rights to acne treatment Fabior (tazarotene) foam and plaque psoriasis treatment Sorilux (calcipotriene) foam. 

August 16, 2016

The New York Times is reporting that the market for osteoporosis drugs might be getting a shakeup soon, as a competitor to Forteo, Eli Lilly & Co.'s osteoporosis treatment, completes a large clinical trial. The new drug uses a hormone that can build bone growth, and its maker, Radius, has an application pending before the Food and Drug Administration that the report says is expected to be approved. (New York Times)

August 15, 2016

Zinbryta is generally reserved for patients with inadequate responses to two or more multiple sclerosis therapies. 

August 10, 2016

Diplomat Pharmacy on Tuesday announced the results of its second quarter, reporting total revenue of $1.09 billion, a 35% increase over the same quarter in 2015.

August 10, 2016

CareTrend allows users to manage their entire workflow operations from a single dashboard that can track output and identify delays while tracking employee productivity in real time.

August 4, 2016

USA Today is reporting that CVS Health has announced plans to remove two biologic drugs, Neupogen and Lantus, from its pharmacy benefits manager (PBM) formulary in 2017 and replace them with biosimilars of the drugs, substituting Zarxio for Neupogen and Basaglar for Lantus. Biosimilars cost about 15% to 30% less than the original biologics. CVS’s EVP and chief medical officer Troyen Brennan told USA Today that the biologics were reviewed by panels of experts “to make sure they are considered equivalent. (USA Today)

August 3, 2016

DSN associate editor David Salazar examines chain pharmacy, including in-depth coverage of pharmacy spending, telehealth, generics and technology, in this multi-page report.

August 2, 2016

Giant Eagle Specialty Pharmacy is dedicated to providing both choice and convenience in addition to offering patients personal support as they manage complex medical conditions, the Western Pennsylvanian retailer said.

August 2, 2016

For the second year in a row, spending on medicines in 2015 grew by double-digits, increasing 12.2% on an invoice basis to $424.8 billion, according to the IMS Institute for Healthcare Informatics’ medicine report on spending for 2015.

August 2, 2016

Among the biosimilars researchers focused on was Inflectra, which was developed by Pfizer’s Hospira as a biosimilar to Janssen Biotech’s Remicade. 

August 1, 2016

The drug can now be used to treat lower limb spasticity in pediatric patients ages 2 years and older. 

August 1, 2016
With the acquisition, Pfizer gains Bamboo’s gene therapy expertise, as well as an advanced recombinant Adeno-associated virus (rAAV) vector design and production technology and a gene therapy manufacturing facility for Phase I/II materials. 
July 25, 2016

Pennsylvania Wolf’s signing of Senate Bill 514 has earned him praise from both the Biotechnology Innovation Organization (BIO) and Pennsylvania Bio.

July 20, 2016

The combined specialty pharmacy will operate as a wholly-owned subsidiary of Kroger, the company stated.

July 20, 2016

The pilot program would allow the Department of Defense to access lower pricing for prescriptions dispensed at community pharmacies.

July 15, 2016
The drug, which combines Gilead’s Sovaldi (sofosbuvir) with an NS5A inhibitor called velpatasvir, is indicated to treat all six strains of hepatitis C, 
July 15, 2016

The new 112,000 square foot facility will expand CVS Health's work to help customers with disease education and provide pharmacy and medication counseling.

July 13, 2016
Reuters is reporting that the FDA’s Arthritis Advisory Board has unanimously recommended Amgen’s biosimilar of AbbVie’s Humira, ABP 501. The panel said that the drug was similar in safety and effectiveness to Humira for rheumatoid arthritis and plaque psoriasis, and it recommended that the biosimilar should also be approved for Crohn’s disease in adults and ulcerative colitis. (Reuters)
July 8, 2016

Xolair can now be used in patients 6 to 11 years of age with moderate to severe persistent allergic asthma.